SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access

Melanoma Clinical Trial

Official title:

SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02507947
• Other study ID #: EORTC-1332
• Status: Withdrawn

Study information

• Verified date: July 2018
• Source: European Organisation for Research and Treatment of Cancer - EORTC
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

SPECTAmel is a standardized, quality-assured molecular screening platform for tumor characterization and storage of human biological material (HBM) for the purpose of integrating new biomarkers into clinical trials and optimizing access of patients to therapeutic biomarker-driven clinical trials. HBM and clinical/pathological data are collected from consenting patients.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: January 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologically confirmed melanoma of any stage (the steering committee will decide on which stage to include at any particular time point during this trial, this will be communicated appropriately to all participating sites)

• Mandatory availability of adequate human biological material (HBM): FFPE tissue sample from the primary tumor, recurrent tumor, metastasis, obtained at the time of primary surgery/biopsy; minimal amount requested is detailed in the HBM guidelines; if feasible, inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional;

• Age = 18 years;

• At least three months life-expectancy;

• Written informed consent according to ICH/GCP and national/local regulations;

• Absence of any active malignancy, except pT1-2 prostatic cancer Gleason score < 6, or carcinoma in situ of the cervix, in the 5 years before study entry;

• Absence of exclusion criteria like active hepatitis B/C or HIV, second malignancies, no severe organ dysfunction or other comorbidities that may prevent inclusion into clinical trials.

• Central confirmation of human biological material (HBM) adequacy for step 2:

• Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening.

Exclusion Criteria:

• active hepatitis B/C or HIV

• second malignancies

• severe organ dysfunction or other comorbidities

Related Conditions & MeSH terms

• Melanoma

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of screened patients		5 years
Primary	Number of downstream clinical trials;		5 years
Primary	Number of patients enrolled in the downstream therapeutic trials		5 years
Primary	Number of exploratory/future research projects		5 years